Safety of mRNA BNT162b2 COVID-19 (Pfizer-BioNtech) vaccine in children aged 5-11 years: Author's reply to correspondence

Safety of mRNA BNT162b2 COVID-19 (Pfizer-BioNtech) vaccine in children aged 5-11 years: Author's reply to correspondence

Dear Editor, We would like to reply to "Safety of mRNA BNT162b2 COVID-19 (Pfizer-BioNtech) vaccine in children aged 5-11years: Correspondence" regarding our article entitled "Safety of mRNA BNT162b2 COVID-19 (Pfizer-BioNTech) vaccine in children aged 5-11years: Results from an active...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Human vaccines & immunotherapeutics 2023-12, Vol.19 (1), p.2168947-2168947
Hauptverfasser: Ripabelli, Giancarlo, Salzo, Angelo, Tamburro, Manuela
Format: Artikel
Sprache:eng
Schlagworte:
BNT162 Vaccine
Child
Coronavirus – Letter
COVID-19 - prevention & control
Humans
Italy - epidemiology
Letter to the Editor
RNA, Messenger
Vaccines
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 2168947
container_issue 1
container_start_page 2168947
container_title Human vaccines & immunotherapeutics
container_volume 19
creator Ripabelli, Giancarlo
Salzo, Angelo
Tamburro, Manuela
description Dear Editor, We would like to reply to "Safety of mRNA BNT162b2 COVID-19 (Pfizer-BioNtech) vaccine in children aged 5-11years: Correspondence" regarding our article entitled "Safety of mRNA BNT162b2 COVID-19 (Pfizer-BioNTech) vaccine in children aged 5-11years: Results from an active pharmacovigilance study in central Italy."
doi_str_mv 10.1080/21645515.2023.2168947
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2767172044</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><doaj_id>oai_doaj_org_article_6a43dbc7461b43dcba1cbe25c32e7100</doaj_id><sourcerecordid>2767172044</sourcerecordid><originalsourceid>FETCH-LOGICAL-c482t-7ca344159610991e7ec49566cc32bfa4eb7c42a3060b1e34584540dd9c98c7553</originalsourceid><addsrcrecordid>eNp9kk1v1DAQhiMEolXpTwD5RjlksR1_JBwQ2-VrpWqLoCBuljOZ7LpK4sXOtg2_niy7XdELvnhm_M4ztvwmyXNGJ4zm9DVnSkjJ5IRTnk3GLC-EfpQcb-uplOLn40PM5FFyGuM1HZemXCj1NDnKlJIyy7Pj5O6brbEfiK9J-3UxJeeLK6Z4ycns8sf8fcoKcvaldr8xpOfOL3qE1StyYwFch8R1BFauqQJ2xC6xIjJljAxoQ3xDppt-5cPLSAKum4H0noAPAePadxV2gM-SJ7VtIp7u95Pk-8cPV7PP6cXlp_lsepGCyHmfarCZEEwWitGiYKgRRCGVAsh4WVuBpQbBbUYVLRlmQuZCClpVBRQ56PGRJ8l8x628vTbr4FobBuOtM38LPiyNDb2DBo2yIqtK0EKxcoygtAxK5HIchZpROrLe7ljrTdliBdj1wTYPoA9POrcyS39jiiKnMmcj4GwPCP7XBmNvWhcBm8Z26DfRcK0005wKMUrlTgrBxxiwPoxh1GxNYO5NYLYmMHsTjH0v_r3joev-y0fBu53AdbUPrb31oalMb4fGhzrYDlw02f9n_AGov74a</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2767172044</pqid></control><display><type>article</type><title>Safety of mRNA BNT162b2 COVID-19 (Pfizer-BioNtech) vaccine in children aged 5-11 years: Author's reply to correspondence</title><source>Taylor &amp; Francis Open Access</source><source>MEDLINE</source><source>DOAJ Directory of Open Access Journals</source><source>PubMed Central</source><source>Alma/SFX Local Collection</source><creator>Ripabelli, Giancarlo ; Salzo, Angelo ; Tamburro, Manuela</creator><creatorcontrib>Ripabelli, Giancarlo ; Salzo, Angelo ; Tamburro, Manuela</creatorcontrib><description>Dear Editor, We would like to reply to "Safety of mRNA BNT162b2 COVID-19 (Pfizer-BioNtech) vaccine in children aged 5-11years: Correspondence" regarding our article entitled "Safety of mRNA BNT162b2 COVID-19 (Pfizer-BioNTech) vaccine in children aged 5-11years: Results from an active pharmacovigilance study in central Italy."</description><identifier>ISSN: 2164-5515</identifier><identifier>EISSN: 2164-554X</identifier><identifier>DOI: 10.1080/21645515.2023.2168947</identifier><identifier>PMID: 36655383</identifier><language>eng</language><publisher>United States: Taylor &amp; Francis</publisher><subject>BNT162 Vaccine ; Child ; Coronavirus – Letter ; COVID-19 - prevention &amp; control ; Humans ; Italy - epidemiology ; Letter to the Editor ; RNA, Messenger ; Vaccines</subject><ispartof>Human vaccines &amp; immunotherapeutics, 2023-12, Vol.19 (1), p.2168947-2168947</ispartof><rights>2023 The Author(s). Published with license by Taylor &amp; Francis Group, LLC. 2023</rights><rights>2023 The Author(s). Published with license by Taylor &amp; Francis Group, LLC. 2023 The Author(s)</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c482t-7ca344159610991e7ec49566cc32bfa4eb7c42a3060b1e34584540dd9c98c7553</cites><orcidid>0000-0002-9953-7769</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC9980581/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC9980581/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,723,776,780,860,881,2096,27479,27901,27902,53766,53768,59116,59117</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/36655383$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Ripabelli, Giancarlo</creatorcontrib><creatorcontrib>Salzo, Angelo</creatorcontrib><creatorcontrib>Tamburro, Manuela</creatorcontrib><title>Safety of mRNA BNT162b2 COVID-19 (Pfizer-BioNtech) vaccine in children aged 5-11 years: Author's reply to correspondence</title><title>Human vaccines &amp; immunotherapeutics</title><addtitle>Hum Vaccin Immunother</addtitle><description>Dear Editor, We would like to reply to "Safety of mRNA BNT162b2 COVID-19 (Pfizer-BioNtech) vaccine in children aged 5-11years: Correspondence" regarding our article entitled "Safety of mRNA BNT162b2 COVID-19 (Pfizer-BioNTech) vaccine in children aged 5-11years: Results from an active pharmacovigilance study in central Italy."</description><subject>BNT162 Vaccine</subject><subject>Child</subject><subject>Coronavirus – Letter</subject><subject>COVID-19 - prevention &amp; control</subject><subject>Humans</subject><subject>Italy - epidemiology</subject><subject>Letter to the Editor</subject><subject>RNA, Messenger</subject><subject>Vaccines</subject><issn>2164-5515</issn><issn>2164-554X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><sourceid>0YH</sourceid><sourceid>EIF</sourceid><sourceid>DOA</sourceid><recordid>eNp9kk1v1DAQhiMEolXpTwD5RjlksR1_JBwQ2-VrpWqLoCBuljOZ7LpK4sXOtg2_niy7XdELvnhm_M4ztvwmyXNGJ4zm9DVnSkjJ5IRTnk3GLC-EfpQcb-uplOLn40PM5FFyGuM1HZemXCj1NDnKlJIyy7Pj5O6brbEfiK9J-3UxJeeLK6Z4ycns8sf8fcoKcvaldr8xpOfOL3qE1StyYwFch8R1BFauqQJ2xC6xIjJljAxoQ3xDppt-5cPLSAKum4H0noAPAePadxV2gM-SJ7VtIp7u95Pk-8cPV7PP6cXlp_lsepGCyHmfarCZEEwWitGiYKgRRCGVAsh4WVuBpQbBbUYVLRlmQuZCClpVBRQ56PGRJ8l8x628vTbr4FobBuOtM38LPiyNDb2DBo2yIqtK0EKxcoygtAxK5HIchZpROrLe7ljrTdliBdj1wTYPoA9POrcyS39jiiKnMmcj4GwPCP7XBmNvWhcBm8Z26DfRcK0005wKMUrlTgrBxxiwPoxh1GxNYO5NYLYmMHsTjH0v_r3joev-y0fBu53AdbUPrb31oalMb4fGhzrYDlw02f9n_AGov74a</recordid><startdate>20231231</startdate><enddate>20231231</enddate><creator>Ripabelli, Giancarlo</creator><creator>Salzo, Angelo</creator><creator>Tamburro, Manuela</creator><general>Taylor &amp; Francis</general><general>Taylor &amp; Francis Group</general><scope>0YH</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope><scope>DOA</scope><orcidid>https://orcid.org/0000-0002-9953-7769</orcidid></search><sort><creationdate>20231231</creationdate><title>Safety of mRNA BNT162b2 COVID-19 (Pfizer-BioNtech) vaccine in children aged 5-11 years: Author's reply to correspondence</title><author>Ripabelli, Giancarlo ; Salzo, Angelo ; Tamburro, Manuela</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c482t-7ca344159610991e7ec49566cc32bfa4eb7c42a3060b1e34584540dd9c98c7553</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2023</creationdate><topic>BNT162 Vaccine</topic><topic>Child</topic><topic>Coronavirus – Letter</topic><topic>COVID-19 - prevention &amp; control</topic><topic>Humans</topic><topic>Italy - epidemiology</topic><topic>Letter to the Editor</topic><topic>RNA, Messenger</topic><topic>Vaccines</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Ripabelli, Giancarlo</creatorcontrib><creatorcontrib>Salzo, Angelo</creatorcontrib><creatorcontrib>Tamburro, Manuela</creatorcontrib><collection>Taylor &amp; Francis Open Access</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><collection>DOAJ Directory of Open Access Journals</collection><jtitle>Human vaccines &amp; immunotherapeutics</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Ripabelli, Giancarlo</au><au>Salzo, Angelo</au><au>Tamburro, Manuela</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Safety of mRNA BNT162b2 COVID-19 (Pfizer-BioNtech) vaccine in children aged 5-11 years: Author's reply to correspondence</atitle><jtitle>Human vaccines &amp; immunotherapeutics</jtitle><addtitle>Hum Vaccin Immunother</addtitle><date>2023-12-31</date><risdate>2023</risdate><volume>19</volume><issue>1</issue><spage>2168947</spage><epage>2168947</epage><pages>2168947-2168947</pages><issn>2164-5515</issn><eissn>2164-554X</eissn><abstract>Dear Editor, We would like to reply to "Safety of mRNA BNT162b2 COVID-19 (Pfizer-BioNtech) vaccine in children aged 5-11years: Correspondence" regarding our article entitled "Safety of mRNA BNT162b2 COVID-19 (Pfizer-BioNTech) vaccine in children aged 5-11years: Results from an active pharmacovigilance study in central Italy."</abstract><cop>United States</cop><pub>Taylor &amp; Francis</pub><pmid>36655383</pmid><doi>10.1080/21645515.2023.2168947</doi><tpages>1</tpages><orcidid>https://orcid.org/0000-0002-9953-7769</orcidid><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 2164-5515
ispartof Human vaccines & immunotherapeutics, 2023-12, Vol.19 (1), p.2168947-2168947
issn 2164-5515
2164-554X
language eng
recordid cdi_proquest_miscellaneous_2767172044
source Taylor & Francis Open Access; MEDLINE; DOAJ Directory of Open Access Journals; PubMed Central; Alma/SFX Local Collection
subjects BNT162 Vaccine
Child
Coronavirus – Letter
COVID-19 - prevention & control
Humans
Italy - epidemiology
Letter to the Editor
RNA, Messenger
Vaccines
title Safety of mRNA BNT162b2 COVID-19 (Pfizer-BioNtech) vaccine in children aged 5-11 years: Author's reply to correspondence
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-19T21%3A02%3A55IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Safety%20of%20mRNA%20BNT162b2%20COVID-19%20(Pfizer-BioNtech)%20vaccine%20in%20children%20aged%205-11%20years:%20Author's%20reply%20to%20correspondence&rft.jtitle=Human%20vaccines%20&%20immunotherapeutics&rft.au=Ripabelli,%20Giancarlo&rft.date=2023-12-31&rft.volume=19&rft.issue=1&rft.spage=2168947&rft.epage=2168947&rft.pages=2168947-2168947&rft.issn=2164-5515&rft.eissn=2164-554X&rft_id=info:doi/10.1080/21645515.2023.2168947&rft_dat=%3Cproquest_cross%3E2767172044%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2767172044&rft_id=info:pmid/36655383&rft_doaj_id=oai_doaj_org_article_6a43dbc7461b43dcba1cbe25c32e7100&rfr_iscdi=true